Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO)

Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO) — VMCI valuation read

Composite valuation read on 4111.TWO: VMCI 65/100 against a Healthcare sector median of 50. The 15-point above-median print is the headline number for Chi Sheng Pharma & Biotech Co., Ltd, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 4111.TWO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 4111.TWO: 4111.TWO trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -2.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

4111.TWO rose 0.7% over the trailing 7 days, with a +1.4% read on a 30-day basis.